3 Formulation and Enzyme Maker Stocks With a Strong Future Roadmap: Alkem Laboratories, Lincoln Pharmaceuticals and Advanced Enzyme Technologies

Formulation and enzyme maker stocks give investors exposure to medicines, export formulations and enzymes for health and food. Product launches, export orders and margins decide how much of that demand turns into profit.

This list covers three formulation and enzyme maker stocks: Alkem Laboratories for branded generics franchise, Lincoln Pharmaceuticals for export formulation range and Advanced Enzyme Technologies for enzymes and probiotics range. Every figure comes from the latest reported financials and the 9 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Formulation and Enzyme Maker Stocks?

Formulation and enzyme maker stocks are shares of companies that make branded generics, export formulations and enzymes. Results depend on product launches, export orders and margins, so margins and product mix separate the stronger names.

Formulation and Enzyme Maker Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three formulation and enzyme maker stocks as of the 9 Oct 2026 close.

Among pharma and biotech stocks, all three trade at a discount to their industry P/E multiples.

Why Do Formulation and Enzyme Maker Stocks Have a Strong Roadmap in India?

Formulation and enzyme maker stocks have a strong roadmap in India because health spending, generic substitution and demand for enzymes in food and nutrition support steady growth. Three drivers stand out.

• Generic demand: Branded generics gain from price-sensitive prescriptions.
• Export markets: Overseas orders widen the revenue base.
• Enzyme uses: Food, nutrition and feed users add new demand.

Alkem Laboratories: Domestic Brands and Generics Drive the Pipeline

Alkem's roadmap rests on branded generics in India along with generic exports and a presence in international markets, with a mix of domestic brands and exports supporting earnings.

Revenue grew from Rs 10,796.84 crore in FY22 to Rs 15,295.62 crore in FY26, a 41.7% rise, and FY26 revenue was 13.7% higher than FY25. FY26 net profit rose 6.2% to Rs 2,353.13 crore. Over four years, net profit rose from Rs 1,680.32 crore in FY22 to Rs 2,353.13 crore. In Q1 FY27, revenue grew 11.0% to Rs 3,892.90 crore. Operating margin was 23.20% in FY26 and 24.57% in Q1 FY27 against 26.36% a year earlier.

Debt to equity is 0.15 and return on equity is 16.66%. FY26 operating cash flow was Rs 1,963.03 crore against capital expenditure of Rs 617.26 crore. Alkem paid a dividend of Rs 53 per share for FY26, a yield of 1.01%. At a P/E of 28.43 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The Q1 FY27 operating margin of 24.57% was below the 26.36% of a year earlier.

Lincoln Pharmaceuticals: Formulations for India and Export Markets Build the Next Leg

Lincoln Pharma's roadmap rests on formulations sold in India and emerging export markets, with a broad product list supporting revenue.

Revenue grew from Rs 482.12 crore in FY22 to Rs 704.48 crore in FY26, a 46.1% rise, and FY26 revenue was 9.1% higher than FY25. FY26 net profit rose 6.7% to Rs 87.89 crore. Over four years, net profit rose from Rs 69.36 crore in FY22 to Rs 87.89 crore. In Q1 FY27, revenue grew 19.0% to Rs 201.54 crore, and net profit rose 30.9% to Rs 36.23 crore.

Debt to equity is 0.01 and return on equity is 11.60%. The dividend yield is 0.32%. At a P/E of 11.64 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The P/E of 11.64 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Advanced Enzyme Technologies: Enzymes and Probiotics Build the Next Leg

Advanced Enzyme's roadmap rests on enzymes and probiotics for food, nutrition, pharma and animal feed, with a wide industrial customer base supporting revenue.

Revenue grew from Rs 535.80 crore in FY22 to Rs 780.59 crore in FY26, a 45.7% rise, and FY26 revenue was 16.5% higher than FY25. FY26 net profit rose 29.6% to Rs 173.61 crore. Over four years, net profit rose from Rs 123.80 crore in FY22 to Rs 173.61 crore. In Q1 FY27, revenue grew 4.1% to Rs 202.81 crore. Operating margin was 37.06% in FY26 and 33.72% in Q1 FY27 against 35.11% a year earlier.

Debt to equity is 0.02 and return on equity is 10.34%. FY26 operating cash flow was Rs 156.78 crore against capital expenditure of Rs 52.38 crore. Advanced Enzyme paid a dividend of Rs 5.35 per share for FY26, a yield of 2.02%. At a P/E of 17.28 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 33.72% against 37.06% for FY26, so margin stability is the figure to follow as volumes grow.

Best Formulation and Enzyme Maker Stocks in India: Alkem vs Lincoln Pharma vs Advanced Enzyme on Key Financials

Among the best formulation and enzyme maker stocks in India, Alkem leads on return on equity; Lincoln Pharma leads on Q1 FY27 revenue growth and the lowest P/E; Advanced Enzyme leads on FY26 revenue growth and FY26 net profit growth. The table puts the numbers side by side.

Pharma earnings follow product launches, export orders and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Formulation and Enzyme Maker Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen formulation and enzyme maker stocks and shortlist formulation and enzyme maker stocks to buy.

1. Compare each stock's P/E with its industry P/E, which is 37.59 for all three here.
2. Check margins and the share of revenue from exports.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these formulation and enzyme maker stocks

Risks to Consider Before Investing in Formulation and Enzyme Maker Stocks

• Margins: Alkem's Q1 FY27 operating margin of 24.57% was below the 26.36% of a year earlier.
• Price controls: Drug price rules can limit pricing.
• Regulatory checks: Plant inspections can delay supply.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Alkem, Lincoln Pharma and Advanced Enzyme live.

Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.

Comparing a quarter with the same quarter of the previous year gives a cleaner reading than comparing it with the preceding quarter, since seasonal patterns affect many businesses in India.

The shareholding pattern published every quarter shows whether promoters, mutual funds and foreign investors are raising or trimming their holdings, which adds useful context to the financial numbers.

Spreading money across several sectors and company sizes helps keep a portfolio steady, because each business responds differently to interest rates, commodity prices and consumer demand.

Final Take: Which Stock Has the Strongest Roadmap?

These three pharma and biotech stocks cover branded generics, export formulations and enzymes. Alkem leads on return on equity; Lincoln Pharma leads on Q1 FY27 revenue growth and the lowest P/E; Advanced Enzyme leads on FY26 revenue growth and FY26 net profit growth.

Across formulation and enzyme maker stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the formulation and enzyme maker stocks to buy discussed here.

FAQs on Formulation and Enzyme Maker Stocks

Which are the best formulation and enzyme maker stocks in India with a strong roadmap?

Ans. Alkem Laboratories, Lincoln Pharmaceuticals and Advanced Enzyme Technologies stand out for their roadmaps in branded generics, export formulations and enzymes. FY26 revenue growth was 13.7% at Alkem, 9.1% at Lincoln Pharma and 16.5% at Advanced Enzyme, and return on equity ranges from 10.34% to 16.66%.

Is Alkem Laboratories a good stock to buy now?

Ans. Alkem Laboratories has a debt to equity ratio of 0.15, a return on equity of 16.66% and a P/E of 28.43 against an industry P/E of 37.59. Valuation, regulation and product mix move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Alkem, Lincoln Pharma and Advanced Enzyme?

Ans. The P/E ratio is 28.43 for Alkem (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 17.28 for Advanced Enzyme (industry 37.59). All of them trade below the industry multiple.

Which of these formulation and enzyme maker stocks has the highest return on equity?

Ans. Alkem Laboratories has the highest return on equity at 16.66%, followed by Lincoln Pharmaceuticals at 11.60% and Advanced Enzyme Technologies at 10.34%.

What are the risks of investing in formulation and enzyme maker stocks?

Ans. The main risks are margins, price controls, regulatory checks and quarterly trends. Alkem's Q1 FY27 operating margin of 24.57% was below the 26.36% of a year earlier.

How did Alkem, Lincoln Pharma and Advanced Enzyme perform in Q1 FY27?

Ans. Alkem Laboratories reported revenue of Rs 3,892.90 crore, up 11.0% year on year. Lincoln Pharmaceuticals reported revenue of Rs 201.54 crore, up 19.0% year on year, and net profit rose 30.9% to Rs 36.23 crore. Advanced Enzyme Technologies reported revenue of Rs 202.81 crore, up 4.1% year on year.

Do formulation and enzyme maker stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 1.01% for Alkem, 0.32% for Lincoln Pharma and 2.02% for Advanced Enzyme, based on dividends declared for FY26.

How can I invest in formulation and enzyme maker stocks in India?

Ans. You can buy formulation and enzyme maker stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.